Real-world study of first-line chemotherapy in combination with bevacizumab for advanced non-small cell lung cancer

WANG Bing; WANG Yuting; LI Jinfeng; LIU Fei; WANG Ying; CHEN Weina; DONG Haozhen; ZHANG Yuan; SUN Tong

doi:10.13506/j.cnki.jpr.2025.03.013

Abstract：Objective To compare the safety and efficacy of domestic biological analogue Bevacizumab Injection(Ankeda)and the original research drug Bevacizumab Injection(Avastin)in the treatment of advanced non-small cell lung cancer patients.Methods Total of 66 patients with advanced non-small cell lung cancer admitted to Weihai Municipal Hospital from January 2020 to December 2021 were selected,of which 28 patients were treated with the chemo-therapy regimen pemetrexed+platinum+bevacizumab(Avastin)as the control group and the chemotherapy regimen was pemetrexed+platinum+bevacizumab(Ankeda)as the experimental group,with a total of 38 cases.The objective response rate(ORR)at week 12 was used as the primary endpoint,while objective response rates(ORR)at week 18,24,duration of response(DOR),disease control rate(DCR),progression free survival(PFS),overall survival(OS),and safety assessment were used as secondary endpoints.Results In the survival function of 66 patients,there was no significant difference in the effect of time to survival between the Ankeda and Avastin groups(P＞0.05),and no significant association was found between sex,age,smoking history,tumor stage and metastatic site on PFS and OS in the COX one-way regression analysis(P＞0.05).The main endpoint of the 12th week ORR study was 32.14％in the Avastin group and 65.79％in the Ankeda group(P=0.007);The ORR of the secondary study endpoint at week 18 was 21.43％in the Avastin group and 44.74％in the Ankeda group(P=0.05);The ORR for the 24th week was 14.29％in the Avastin group and 23.68％in the Ankeda group(P=0.343).The patients in the Avastin group had an ORR of 3.57％and a DCR of 14.29％at the end of fol-low-up.And at the end of follow-up,patients in the Ankeda group had an ORR of 15.79％and a DCR of 5.26％,with no statistically significant difference between the two groups(P＞0.05).Among the 66 patients,there were 24 cases of adverse reactions.And there was no statistically significant difference between the occurrence of adverse reactions in the Ankeda and Avastin groups.Conclusion Bevacizumab Injection(Ankeda)has excellent clinical efficacy and survival advantages in the treatment of advanced non-small cell lung cancer with controlled and tolerable adverse effects.There is no statistically sig-nificant difference in clinical efficacy and safety compared to the reference drug Bevaczumab Injection(Avastin).